This systematic review demonstrates that GLP-1 receptor agonists - particularly semaglutide, liraglutide, and tirzepatide - are effective and generally well-tolerated options for achieving and maintaining long-term weight loss in individuals with obesity. The gene discussed is GLP1R; the disease is obesity disorder.